A referral source can look productive when it sends a lot of names or inquiries.
But volume answers only one question: How much activity did the source generate?
The more useful question is what happened next. Did referred candidates engage? Complete intake? Reach site review? Later screen, consent, or randomize?
Referral source performance tracking connects the original source to those stages so a research site can compare patterns across the enrollment pathway without assuming the source caused every downstream result.
Published Research
Published research illustrates why referral volume should not be viewed by itself. The examples below show that referral volume and later progression can tell different stories.
A randomized late-life depression trial reported referral-to-randomization yield by source.
| Source | Referrals | Randomized | Yield |
|---|---|---|---|
| Provider referrals | 33 | 10 | ~30.3% |
| Facebook self-referrals | 323 | 14 | ~4.3% |
Takeaway: The source producing substantially greater referral volume did not produce proportionately greater randomization yield in that individual study.
A multisite recruitment analysis compared how different referral methods performed at different stages of the enrollment pathway.
Takeaway: Referral sources may perform differently at different stages of the enrollment pathway.
Study-specific findings. Not industry benchmarks.
Referral volume measures activity. Stage-level progression helps reveal what that activity produces.
Referral source tracking only works if the original source or channel stays connected to the candidate record.
That might be a physician referral, digital campaign, site database, patient community, recruitment vendor, outreach program, or another approved source.
When that attribution remains visible as the candidate progresses, the site can ask more useful questions than simply: How many referrals did we get?
Those comparisons can reveal patterns worth reviewing. They do not prove that the referral source caused what happened later.
Study population, geography, protocol requirements, candidate characteristics, site processes, study burden, timing, accessibility, and other factors may all affect progression.
For the broader operational context, see clinical trial referral management best practices, the referral-to-randomization workflow, and enrollment metrics every research site should track.
Instead of trying to judge a source with one number, it is more useful to look at three levels of the pathway.
This is the starting point. Referral volume shows how much activity entered the pathway before any operational follow-up occurs.
The number of inquiries or referrals attributed to a source during a defined period.
This answers: How much activity is this source generating?
Referral volume matters, but a large number of referrals does not by itself establish source quality or enrollment effectiveness. It tells you how much activity entered the pathway, not what happened next.
The next level looks at what happens during the supported pre-consent workflow before formal research-site screening.
How many referrals progress into meaningful contact or engagement under the site's defined workflow.
This answers: How much of the referral activity becomes actionable?
Sites may define contact and response statuses differently, so no universal contact-rate formula is imposed here.
How many referred candidates complete the preliminary information needed for research-site review.
This answers: How much of the referral activity reaches a review-ready stage?
The proportion of candidates whose reported information remains consistent with the site-approved criteria evaluated during preliminary prescreening.
This answers: What does the candidate-reported information indicate before formal site screening?
Preliminary criteria alignment is not a determination of eligibility. The research site remains responsible for formal screening and final eligibility decisions.
The time from referral receipt through the supported pre-consent workflow until the candidate's preliminary information is ready for site review or structured handoff.
This answers: How quickly does referral activity reach a review-ready state?
This measures the interval from referral receipt through structured site handoff. It is not a time-to-randomization metric.
The third level looks at outcomes after responsibility has moved into the research site's clinical process. Reliable source attribution is necessary if the site wants to connect these later outcomes back to the original referral source.
Downstream screening outcomes associated with the original referral source when source attribution remains connected to the candidate record.
This answers: What happens after formal site screening begins?
A recurring source-specific pattern may give the site something to investigate. The site may review the actual reasons for screen failure and ask whether any recurring factor could reasonably and appropriately have been identified earlier through the site's approved preliminary workflow. The pattern itself does not establish the cause.
Randomized participants originating from a source divided by the total referrals received from that source.
This answers: What ultimate downstream outcome was associated with the original referral source?
Referral-to-randomization yield should be interpreted alongside the earlier stages. Many factors between referral and randomization are outside the referral source's control. The research site retains responsibility for formal screening, final eligibility decisions, informed consent, protocol oversight, medical decisions, and randomization. No single metric is universally the most important.
Consider a fictional example:
Illustrative example only. Not benchmark data.
| Source | Referrals | Intake Completed | Preliminary Alignment | Screened | Randomized | Referral → Randomization Yield |
|---|---|---|---|---|---|---|
| Source A | 200 | 110 | 52 | 28 | 10 | 5.0% |
| Source B | 80 | 61 | 43 | 31 | 15 | 18.75% |
| Source C | 40 | 34 | 27 | 22 | 12 | 30.0% |
Source A generated the most referrals, but it did not produce the highest downstream yield.
Source C generated far fewer referrals, yet a larger proportion of those referrals ultimately reached randomization in this fictional example.
That does not make Source C automatically "better."
The sources could differ in population, reach, accessibility, cost, representativeness, candidate burden, recruitment strategy, protocol fit, or many other factors.
The table simply demonstrates why each stage tells a different part of the story.
These values are fictional and do not represent typical clinical-trial performance.
A pattern gives the site something to investigate.
It does not automatically tell the site what caused the pattern or what should be changed.
High referral volume with low engagement
This may justify reviewing candidate expectations, messaging, candidate readiness, referral context, or the intake process before concluding that the source itself is low quality.
Strong preliminary criteria alignment with recurring downstream screen failures
Review the actual reasons for screen failure. The useful question is whether a recurring factor could reasonably and appropriately have been identified earlier through the site's approved preliminary workflow.
Longer pre-consent processing time from one source
This may reflect greater missing-information, follow-up, or engagement needs associated with that source rather than a problem with the source itself.
Strong downstream outcomes associated with a source
That may be a reason to make sure the site's responsiveness and available capacity are sufficient to support the activity coming from that source.
A site may also need to consider:
A source that looks weaker on one metric may still be important for access, population representativeness, or another study objective. Use the data to decide what to examine next, not to jump directly from a pattern to a conclusion.
For related workflow questions, see referral follow-up workflows for clinical trials, coordinator capacity, and coordinator workload management for research sites.
Consent2Randomize can support different parts of the enrollment pathway depending on the study.
If recruitment is in scope: C2R may help generate potential-participant interest through the study-approved recruitment approach and preserve the originating source or channel attribution through the agreed workflow.
If post-interest enrollment support is in scope: C2R may support approved intake, site-approved preliminary prescreening, follow-up, scheduling coordination, documentation, escalation, and structured site handoff.
If both are in scope: The agreed workflow can preserve recruitment-source attribution while also tracking activity through the C2R-supported post-interest portion of the pathway.
A study may use recruitment only, post-interest enrollment support only, or both. See Clinical Trial Enrollment Support for the study-specific service model.
Reliable comparison depends on keeping the original source or channel connected to the candidate as the person moves through the pathway. When post-interest support is included, structured clinical trial intake and site-approved preliminary prescreening can add stage-level information while preserving that attribution.
If later research-site outcomes remain connected to the original candidate and source record, the site can look across the broader pathway without implying that C2R or the referral source controlled those downstream outcomes. The referral-to-randomization calculator and enrollment operations KPI dashboard can also help organize that pathway view.
The research site retains responsibility for formal screening, final eligibility decisions, informed consent, protocol oversight, medical decisions, and randomization.
Provider referrals versus Facebook self-referrals in a randomized late-life depression trial.
Multisite comparison of referral methods across screened, consenting, and randomized stages.
Used where this page distinguishes preliminary prescreening from formal study eligibility and screening.
Related Resources
Continue Reading
Have an active or upcoming study?
We can look at where potential participants are expected to come from, what happens after interest or referral arrives, how source attribution can stay visible through the early enrollment workflow, and whether any part of that work would be useful for C2R to support.
It is a study-specific scoping conversation, not a referral-source performance audit or guarantee.
